Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Apr 5;4(4):CD007731.
doi: 10.1002/14651858.CD007731.pub3.

Ganoderma lucidum (Reishi mushroom) for cancer treatment

Xingzhong Jin  1 , Julieta Ruiz Beguerie, Daniel Man-Yeun Sze, Godfrey C F Chan
Affiliations
Meta-Analysis

Ganoderma lucidum (Reishi mushroom) for cancer treatment

Xingzhong Jin et al. Cochrane Database Syst Rev. .

Abstract

Background: Ganoderma lucidum is a natural medicine that is widely used and recommended by Asian physicians and naturopaths for its supporting effects on immune system. Laboratory research and a handful of preclinical trials have suggested that G. lucidum carries promising anticancer and immunomodulatory properties. The popularity of taking G. lucidum as an alternative medicine has been increasing in cancer patients. However, there is no systematic review that has been conducted to evaluate the actual benefits of G. lucidum in cancer treatment.

Objectives: To evaluate the clinical effects of G. lucidum on long-term survival, tumour response, host immune functions and quality of life in cancer patients, as well as adverse events associated with its use.

Search methods: We searched an extensive set of databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, NIH, AMED, CBM, CNKI, CMCC and VIP Information/Chinese Scientific Journals Database was searched for randomised controlled trials (RCTs) in October 2011. Other strategies used were scanning the references of articles retrieved, handsearching of the International Journal of Medicinal Mushrooms and contact with herbal medicine experts and manufacturers of G. lucidum. For this update we updated the searches in February 2016.

Selection criteria: To be eligible for being included in this review, studies had to be RCTs comparing the efficacy of G. lucidum medications to active or placebo control in patients with cancer that had been diagnosed by pathology. All types and stages of cancer were eligible for inclusion. Trials were not restricted on the basis of language.

Data collection and analysis: Five RCTs met the inclusion criteria and were included in this review. Two independent review authors assessed the methodological quality of individual trials. Common primary outcomes were tumour response evaluated according to the World Health Organization (WHO) criteria, immune function parameters such as natural killer (NK)-cell activity and T-lymphocyte co-receptor subsets, and quality of life measured by the Karnofsky scale score. No trial had recorded long-term survival rates. Associated adverse events were reported in one study. A meta-analysis was performed to pool available data from the primary trials. Results were gauged using relative risks (RR) and standard mean differences (SMD) for dichotomous and continuous data respectively, with a 95% confidence interval (CI).

Main results: The methodological quality of primary studies was generally unsatisfying and the results were reported inadequately in many aspects. Additional information was not available from primary trialists. The meta-analysis results showed that patients who had been given G. lucidum alongside with chemo/radiotherapy were more likely to respond positively compared to chemo/radiotherapy alone (RR 1.50; 95% CI 0.90 to 2.51, P = 0.02). G. lucidum treatment alone did not demonstrate the same regression rate as that seen in combined therapy. The results for host immune function indicators suggested that G. lucidum simultaneously increases the percentage of CD3, CD4 and CD8 by 3.91% (95% CI 1.92% to 5.90%, P < 0.01), 3.05% (95% CI 1.00% to 5.11%, P < 0.01) and 2.02% (95% CI 0.21% to 3.84%, P = 0.03), respectively. In addition, leukocyte, NK-cell activity and CD4/CD8 ratio were marginally elevated. Four studies showed that patients in the G. lucidum group had relatively improved quality of life in comparison to controls. One study recorded minimal side effects, including nausea and insomnia. No significant haematological or hepatological toxicity was reported.

Authors' conclusions: Our review did not find sufficient evidence to justify the use of G. lucidum as a first-line treatment for cancer. It remains uncertain whether G. lucidum helps prolong long-term cancer survival. However, G. lucidum could be administered as an alternative adjunct to conventional treatment in consideration of its potential of enhancing tumour response and stimulating host immunity. G. lucidum was generally well tolerated by most participants with only a scattered number of minor adverse events. No major toxicity was observed across the studies. Although there were few reports of harmful effect of G. lucidum, the use of its extract should be judicious, especially after thorough consideration of cost-benefit and patient preference. Future studies should put emphasis on the improvement in methodological quality and further clinical research on the effect of G. lucidum on cancer long-term survival are needed. An update to this review will be performed every two years.

PubMed Disclaimer

Conflict of interest statement

None of the authors is involved in clinical trials or have direct financial interest in the subject matter of this review.

Figures

1.1
1.1. Analysis
Comparison 1 Treatment response, Outcome 1 WHO criteria.
2.1
2.1. Analysis
Comparison 2 Host immune functions, Outcome 1 Leukocyte.
2.2
2.2. Analysis
Comparison 2 Host immune functions, Outcome 2 NK activity.
2.3
2.3. Analysis
Comparison 2 Host immune functions, Outcome 3 CD3.
2.4
2.4. Analysis
Comparison 2 Host immune functions, Outcome 4 CD4.
2.5
2.5. Analysis
Comparison 2 Host immune functions, Outcome 5 CD8.
2.6
2.6. Analysis
Comparison 2 Host immune functions, Outcome 6 CD4/CD8.
3.1
3.1. Analysis
Comparison 3 Quality of life, Outcome 1 Karnofsky score (dichotomous)).
3.2
3.2. Analysis
Comparison 3 Quality of life, Outcome 2 Karnofsky score.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Gao 2003b {published data only}
    1. Gao Y, Dai X, Chen G, Ye J, Zhou S. A randomized, placebo‐controlled, multicenter study of Ganoderma lucidum (w.curt.:fr.) Lloyd (aphyllophoromycetideae) polysaccharides (ganopoly) in patients with advanced lung cancer. International Journal of Medicinal Mushrooms 2003;5(4):369‐81.
He 1997 {published data only}
    1. He W, Yi J. Study of clinical efficacy of Lingzhi spore capsule on tumour patients with chemotherapy/radiotherapy. Clinical Journal of Traditional Chinese Medicine 1997;9(6):292‐3.
Leng 2003 {published data only}
    1. Leng K, Lu M. Investigation of ZhengQing Lingzhi liquid as adjuvant treatment on patients with colon cancer. Journal of Guiyang Medical College 2003;28(5):1.
Yan 1998 {published data only}
    1. Yan B, Wei Y, Li Y. Effect of Laojunxian Lingzhi oral liquid combined with chemotherapy on non‐parvicellular lung cancer at stage II and III. Traditional Chinese Drug Research & Clinical Pharmacology 1998;9(2):78‐80.
Zhang 2000 {published data only}
    1. Zhang X, Jia Y, Li Q, Niu S, Zhu S, Shen C. Clinical curative effect investigation of Lingzhi tablet on lung cancer. Chinese Traditional Patent Medicine 2000;22(7):486‐8.

References to studies excluded from this review

Chen 2006 {published data only}
    1. Chen X, Hu ZP, Yang XX, Huang M, Gao Y, Tang W, et al. Monitoring of immune responses to a herbal immuno‐modulator in patients with advanced colorectal cancer. International Immunopharmacology 2006;6(3):499‐508. - PubMed
Gao 2003a {published data only}
    1. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced‐stage cancer patients. Immunological Investigations 2003;32(3):201‐15. - PubMed
Gao 2004 {published data only}
    1. Gao Y, Tank W, Gao H, Lan J, Zhou S. Chemopreventive, and tumoricidal properties of Ling Zhi mushroom Ganoderma lucidum (w. Curt.:fr.) Lloyd (aphyllophoromycetideae). Part i. Preclinical and clinical studies. International Journal of Medicinal Mushrooms 2004;6(2):95‐106.
Gao 2005a {published data only}
    1. Gao Y, Tang W, Dai X, Gao H, Chen G, Ye J, et al. Effects of water‐soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. Journal of Medicinal Food 2005;8(2):159‐68. - PubMed
Gao 2005b {published data only}
    1. Gao Y, Tang W, Dai X, Gao H, Chen G, Ye J, et al. Immune responses to water‐soluble Ling Zhi mushroom Ganoderma lucidum (W.Curt.:Fr.) P. Karst. Polysaccharides in patients with advanced colorectal cancer. International Journal of Medicinal Mushrooms 2005;7(4):525‐37.
Gill 2008 {published data only}
    1. Gill SK. Rieder MJ. Toxicity of a traditional Chinese medicine, Ganoderma lucidum, in children with cancer. Canadian Journal of Clinical Pharmacology 2008;15(2):e275‐85. - PubMed
Huang 2001 {published data only}
    1. Huang J, Zhong X, Li G. Therapeutic effect of mixture Lingzhi with CD3/NK cell on lung cancer. Modern Journal of Integrated Traditional Chinese and Western Medicine 2001;10(8):704‐5.
Jia 2005 {published data only}
    1. Jia HQ, Wu SH, Wu J. Clinical analysis of Lingzhi spore in prostate cancer treatment. Andrology 2005;9(4):18‐9.
Jing 2007 {published data only}
    1. Jing J, Zhu X, Li B, Jie Y. Clinical comparative investigation of Bailong capsule and liquid in combination with chemotherapy for digestive tumor. Shanxi Medical Journal 2007;36(7):631‐3.
Kuang 2007 {published data only}
    1. Kuang J, Wang J, Kuang J. Investigation of effectiveness of Sporoderm‐Broken Lingzhi spore powder in conjunction with chemotherapy on malignant tumour. Shangdong Medical Journal 2007;47(21):59‐60.
    1. Li Y. Clinical investigation of immunological indications of hematological malignancy. Journal of Guangxi Medical College 2000;17(2):54‐6.
Li 2000 {published data only}
    1. Li G, Cheng H. A Clinical Study on Immunity Regulation Function of Shenqi Lingzhi Regimen on Tumour Patients. Forum On Traditional Chinese Medicine 2000;15(6):29‐30.
Liang 2002 {published data only}
    1. Liang J, Li Y, Wang S. Effect of radiotherapy combined with a medicine Lingzhi‐912 on treatment of esophageal cancer. Journal of The Forth Military Medical University 2002;23(3):278‐80.
Ma 2003 {published data only}
    1. Ma MQ. Immunomodulatory effects of Chen‐Ling anti‐tumour capsule on tumour patients. China's Naturopathy 2003;11(8):38‐9.
Mahajna 2009 {published data only}
    1. Mahajna J, Dotan N, Zaidman BZ, Petrova RD, Wasser SP. Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum. Nutrition & Cancer 61;1:16‐26. - PubMed
Mo 1999 {published data only}
    1. Mo H, Hong M, Zhang J. Effect of Wuse ‐ Lingzhi ‐ Jiaonang on reducing side‐effects of radiotherapy and improving immune function in patients with nasopharyngeal cancer. Chinese Journal of Clinical Oncology 1999;26(3):216‐8.
Niu 2002 {published data only}
    1. Niu Z. Observation of 30 cases of advanced malignant tumours treated by Zhonghua Lingzhi Bao. Shanxi Oncology Medicine 2002;10(3):225‐6.
Pan 2007 {published data only}
    1. Pan S, Sun W. The clinical efficacy study of ginseng and Ganoderma lucidum essence ‐ reinforcing pills combine with chemotherapy for malignant tumours. Liaoning Journal of Traditional Chinese Medicine 2007;34(10):1411‐3.
Qi 1999 {published data only}
    1. Qi Y, Li X, Yan M, Liu A, Jiao Z, Liu H. Clinical investigation of Lingzhi spore powder in adjuvant treatment of digestive tumours. Chinese Journal of Integrated Traditional and Western Medicine 1999;19(9):554‐5.
Simerpal 2008 {published data only}
    1. Gill SK. Rieder MJ. Toxicity of a traditional Chinese medicine, Ganoderma lucidum, in children with cancer. Canadian Journal of Clinical Pharmacology 2008;15(2):e275‐85. - PubMed
Sliva 2003 {published data only}
    1. Sliva D. Ganoderma lucidum (Reishi) in cancer treatment. Integrative Cancer Therapies 2003;2(4):358‐64. - PubMed
Sliva 2006 {published data only}
    1. Sliva D. Ganoderma lucidum in cancer research. Leukemia Research 2006;30(7):767‐8. - PubMed
Song 2006 {published data only}
    1. Song Z, Cong Z, Wei J. Clinical investigation of Bozhi glycopeptide injection combined with chemotherapy for advanced‐stage malignancy. Journal of Nantong University (Medical Sciences) 2006;26(6):474‐5.
Wang 1999 {published data only}
    1. Wang HJ, Zhang H. Clinical research of Lingzhi in cancer treatment. Journal of Dalian Medical College 1999;21(1):29‐31.
Wang 2005 {published data only}
    1. Wang JW. Observation on the side effect of "Gloosy Ganoderma Spores Powder" combined with Qining injection in the treatment of 28 patients with malignant tumor and nursing care. Journal of Qilu Nursing 2005;13(17):1‐2.
Xu 2000 {published data only}
    1. Xu Z, Zhou R, Wei H. Clinical observation of Tian‐an Lingzhi capsule in 120 patients with malignant tumours. The Journal of Pharmaceutical Practice 2000;18(4):197‐9.
Yuen 2005 {published data only}
    1. Yuen JW, Gohel MD. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutrition & Cancer 2005;53(1):11‐7. - PubMed
Zhang 1999 {published data only}
    1. Zhang W, Sun D, Li W, Wei X. Clinical observation of efficacy of Ganoderm Lucidum capsule on induced toxicity of radiotherapy/chemotherapy. Journal of Binzhou Medical College 1999;22(2):141‐2.
Zhou 2001 {published data only}
    1. Zhou J, Zou XX, Zhou JC. Clinical investigation of Lingzhi infusion in adjuvant treatment of tumour. Jiangxi Journal of Traditional Chinese Medicine 2001;32(3):30‐1.
Zhou 2005 {published data only}
    1. Zhou S, Gao Y, Chan E. Clinical trials for medicinal mushrooms: experience with Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Lingzhi mushroom). International Journal of Medicinal Mushrooms 2005;7(1‐2):111‐7.
Zhuang 2009 {published data only}
    1. Zhuang SR, Chen SL, Tsai JH, Huang CC, Wu TC, Liu WS, et al. Effect of citronellol and the Chinese medical herb complex on cellular immunity of cancer patients receiving chemotherapy/radiotherapy. Phytotherapy Research 2009;23(6):785‐90. - PubMed

References to ongoing studies

Matthew 2010 {published data only (unpublished sought but not used)}
    1. Shing MMK. Ling Zhi for cancer children. ClinicalTrials.gov Phase III trial, NCT00575926.

Additional references

Boh 2007
    1. Boh B, Berovic M, Zhang J, Zhi‐Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnology Annual Review 2007;13:265‐301. - PubMed
Brittenden 1996
    1. Brittenden, J, Heys, S. D, Ross, J, Eremin, O. Natural killer cells and cancer. Cancer 1996;77:1226–1243. - PubMed
Brown 2006
    1. Brown GD. Dectin‐1: a signalling non‐TLR pattern recognition receptor. Nature Reviews Immunology 2006;6(1):33‐43. - PubMed
Chan 2005
    1. Chan WK, Lam DT, Law HK, Wong WT, Koo MV, Lau AS, et al. Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy. Journal of Alternative and Complementary Medicine 2005;11(6):1047‐57. - PubMed
Chan 2007
    1. Chan WK, Law HK, Lin ZB, Lau YL, Chan GC. Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley. International Immunology 2007;19(7):891‐9. - PubMed
Chang 1999
    1. Chang ST, Buswell JA. Ganoderma lucidum ‐ a mushrooming medicinal mushroom. International Journal of Medicinal Mushroom 1999;1:139‐46.
Chinn 2000
    1. Chinn S. A simple method for converting an odds ratio to effect size for use in meta‐analysis. Statistics in Medicine 2000;19(22):3127‐31. - PubMed
CONSORT 2010
    1. Kenneth F Schulz, Douglas G Altman, David Moher. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Annals of Internal Medicine. 15‐Feb‐2011;154(4):290‐1. - PubMed
Flanagan 1982
    1. Flanagan JC. Measurement of quality of life: current state of the art. Archives of Physical Medicine and Rehabilitation 1982;63:56‐9. - PubMed
Gantner 2003
    1. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin‐1 and toll‐like receptor 2. The Journal of Experimental Medicine 2003;197(9):1107‐17. - PMC - PubMed
Harbord 2005
    1. Harbord RM, Egger M, Sterne JAC. A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine 2005;25:3443‐57. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring Inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hong 2004
    1. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, et al. Mechanism by which orally administered beta‐1‐3‐glucans enhance the tumoricidal activity of antitumour monoclonal antibodies in murine tumour models. The Journal of Immunology 2004;173(2):797‐806. - PubMed
Jong 1992
    1. Jong SC, Birmingham JM. Medicinal benefits of the mushroom Ganoderma. Advances in Applied Microbiology 1992;37:101‐34. - PubMed
Lee 1998
    1. Lee S, Park S, Oh JW, Yang C. Natural inhibitors for protein prenyl transferase. Planta Medica 1998;64:303‐8. - PubMed
Miller 1981
    1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207‐14. - PubMed
Min 2000
    1. Min BS, Gao JJ, Nakamura N, Hattori M. Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against Meth‐A and LLC tumor cells. Chemical and Pharmaceutical Bulletin 2000;48:1026‐33. - PubMed
ONS 2005
    1. Oncology Nursing Society (ONS). Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. Oncology Nursing Society, 2005.
Park 2003
    1. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Japanese Journal of Clinical Oncology 2003;33(10):533‐7. - PubMed
Patrick 2000
    1. Patrick T, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000;92:205‐16. - PubMed
Steward 2003
    1. Steward BW, Kleihues P, World Health Organization. World Cancer Report 2003. IARC Press, 2003.
Upton 2000
    1. Upton R. American Herbal Pharmacopoeia: Reishi Mushroom. American Herbal Pharmacopoeia, 2000.
WHO 1979
    1. World Health Organization. WHO handbook for reporting results of cancer treatment; Offset Publication No. 48. Geneva (Switzerland): Would Health Organization Offset Publication, 1979.
Zheng 2011
    1. Sheng Zheng, Yanping Jia, Jun Zhao, Qun Wei, Yuehua Liu. Ganoderma lucidum polysaccharides eradicates the blocking effect of fibrinogen on NK cytotoxicity against melanoma cells. Oncology Letters December 6, 2011;3(3):613‐616. - PMC - PubMed

MeSH terms

Substances